K. Shakeri-Nejad

发表

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

K. Rathgen, J. Stangier, H. Stähle, 2008, Journal of clinical pharmacology.

Drug interactions during therapy with three major groups of antimicrobial agents

R. Stahlmann, K. Shakeri-Nejad, K. Shakeri‐Nejad, 2006, Expert opinion on pharmacotherapy.

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous Siponimod: A Randomized, Open-label Study in Healthy Subjects.

E. Legangneux, S. Neelakantham, Swati Dumitras, 2020, Clinical therapeutics.

Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist.

J. Dingemanse, M. Hoch, K. Shakeri-Nejad, 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Are Not Affected by Moderate Hepatic Impairment Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor,

K. Rathgen, J. Stangier, H. Stähle, 2011 .

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.

Elucidation of the Metabolic Pathways and the Resulting Multiple Metabolites of Almorexant, a Dual Orexin Receptor Antagonist, in Humans

W. Wagner-Redeker, G. Hopfgartner, A. Treiber, 2013, Drug Metabolism and Disposition.

ACh receptor partial agonist: pharmacological characterization and phase I

D. Hoyer, G. Bilbe, C. Pryce, 2015 .

Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.

E. Legangneux, N. Pezous, L. Mooney, 2015, Clinical therapeutics.

Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data

S. Neelakantham, C. Kolly, K. Shakeri-Nejad, 2021, Psychopharmacology.

Cardiac Effects of Siponimod (BAF312) Re-initiation After Variable Periods of Drug Discontinuation in Healthy Subjects.

E. Legangneux, M. Gutierrez, N. Pezous, 2016, Clinical therapeutics.

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

E. Legangneux, T. Marbury, Zhenzhong Su, 2017, Neurology: Neuroimmunology & Neuroinflammation.

Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes

S. Neelakantham, Andrea J Feller, Swati Dumitras, 2019, European Journal of Clinical Pharmacology.

Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence

F. Dahlke, M. Bigaud, K. Shakeri-Nejad, 2022, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation

D. Hoyer, G. Bilbe, K. Lingenhoehl, 2015, British journal of pharmacology.

Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension

R. Zimlichman,, J. Dingemanse, E. Klainman, 2014, Journal of Human Hypertension.

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study .

E. Legangneux, S. Neelakantham, S. Kalluri, 2017, International journal of clinical pharmacology and therapeutics.

Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker: Early Clinical Studies in Healthy Male Subjects Using Adaptive Designs

Markus S. Mueller, B. Sanderson, J. Dingemanse, 2014, Journal of cardiovascular pharmacology.

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects

G. Rossato, E. Legangneux, P. Pal, 2018, Clinical Pharmacokinetics.

Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects

E. Legangneux, S. Neelakantham, Swati Dumitras, 2018, European Journal of Clinical Pharmacology.